Hepatitis E Diagnostic Tests Market By Test Type (ELISA HEV IgM Test, ELISA HEV IgG Test, RT-PCR Test), By End User (Hospitals, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global hepatitis E diagnostic tests market was valued at $61.69 million in 2021, and is projected to reach $93.5 million by 2031, registering a CAGR of 4.2% from 2022 to 2031.
Hepatitis E is a type of viral infection which leads to liver inflammation caused due to hepatitis E virus (HEV). Hepatitis E virus is a positive-sense, single-stranded, non-enveloped, RNA icosahedral virus and is one of the five known human hepatitis virus (A, B, C, D, and E). The transmission of hepatitis E infection occurs through oral or fecal route which is similar to that of hepatitis A. This condition is temporary and can be treated and recovered if diagnosed at an early stage. However, the infection may lead to serious effects in pregnant women and people with weak immune system, which may further lead to death.
Symptoms of hepatitis E infection are asymptomatic in acute cases, however in some cases the patient may suffer from jaundice, fatigue and nausea. It also includes chronic conditions such as fulminant liver failure or liver cirrhosis which are mainly seen in patients with weakened immune systems and who had a solid organ transplant. There is need for early detection and treatment of the infection, which leads to rise in demands for hepatitis E diagnostics kits as the condition may be life threatening in some cases.
According to World Health Organization (WHO), thousands of acute viral hepatitis infections affect children, adolescents and adults every year which may cause mild diseases and even go undetected. However, in some cases, they can cause severe complications and lead to the death of the person.
It also states that in 2019 alone, an estimated 78,000 deaths occurred due to complications of acute hepatitis A to E infections around the globe. This highlights the rise in number of hepatitis infections in population, which further demands for early diagnosis of the condition. This further propels the sale of hepatitis E diagnostic test kits and subsequently the growth of hepatitis E diagnostic tests market.
Furthermore, certain group of population is at high risk of hepatitis E infection, which includes pregnant women, immunosuppressed people, and people with pre-existing liver disease. Pregnant women are majorly at higher risk of getting HEV genotype 1 infection which is associated with fulminant hepatitis and leads to death in women. In addition, women in second or third trimester are at higher risk of acute liver failure, fetal loss and mortality due to hepatitis E. World Health Organization further states that up to 20–25% of pregnant women can die due to hepatitis E in third trimester of pregnancy. Thus, efficient diagnosis and treatment of the condition is necessary to reduce the mortality rate in pregnant women associated with hepatitis E, which propels the growth of hepatitis E diagnostic tests market.
Furthermore, advancements in the field of diagnosis and treatments drive the market. Several advancements have been done by the researchers and manufacturers in healthcare sector which makes the diagnosis and treatment procedure more efficient and accurate. The development of nucleic acid testing kits and enzyme-linked immunosorbent assay (ELISA) kits, which is based on the detection of specific anti-HEV immunoglobulin M (IgM) antibodies to the virus in the blood of a person, offers high quality, efficiency and accuracy in results. For instance, Human Hepatitis E Virus Antibody (IgG) ELISA Kit offered by Cusabio Technology Llc. is used in the detection of HEV IgG antibody in the serum and plasma and is based on qualitative enzyme immunoassay technique.
Such, new and advanced diagnostic tests kits offered by manufacturers increase the demand for the hepatitis E diagnostics tests kits and accelerate the market growth.Furthermore, rise in funds by governments of various countries and non-government organizations to initiate manufacturing units in the healthcare sector are expected to boost the market growth. Moreover, acquisition and partnerships strategies adopted by key market players are boosting factors for the market.
However, hepatitis E diagnostic kits have limited shelf life. Therefore, there is a crucial need to manage the storage of these kits. In addition, these ELISA kits are to be handled with care, as minor changes in the kit may lead to inaccuracies in range, sensitivity, and precision which provides hindrance to the hepatitis E diagnostic tests market growth. On the contrary, rise in the research and development activities by the key market players and increase in healthcare expenditure have further encouraged many key players to enter emerging markets, thus offering lucrative opportunities for the expansion of the hepatitis E diagnostic tests market.
The hepatitis E diagnostic tests market is segmented on the basis of, test type, end user and region. On the basis of test type, the market is categorized into HEV IgM ELISA Test, HEV IgG ELISA Test, and RT-PCR Test. On the basis of end user, it is segmented into hospitals, diagnostic centers and others (research centers, blood bank, point of care, standalone laboratories). On the basis of region, it is studied across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global hepatitis E diagnostic tests market are Altona Diagnostics GmbH, Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd, Dia.Pro Diagnostic Bioprobes s.r.l, ELITechGroup, PerkinElmer Inc. (Euroimmun Medizinische Labordiagnostika AG), F. Hoffmann-La Roche Ltd., Fortress Diagnostics, Mikrogen Diagnostik, MP Biomedicals , Primerdesign Ltd. and others.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hepatitis e diagnostic tests market analysis from 2021 to 2031 to identify the prevailing hepatitis e diagnostic tests market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hepatitis e diagnostic tests market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hepatitis e diagnostic tests market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Test Type
ELISA HEV IgM Test
ELISA HEV IgG Test
RT-PCR Test
By End User
Hospitals
Diagnostic Centers
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
MP Biomedicals LLP
F. Hoffmann-La Roche Ltd.
Altona Diagnostics
PerkinElmer, Inc
Dia.Pro - Diagnostic Bioprobes s.r.l
Primerdesign Ltd
Mikrogen GmbH
Fortress Diagnostics
ELITechGroup
Beijing Wantai Biolog Pha Ent Co Ltd
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Market dynamics
- 3.4.1.Drivers
- 3.4.2.Restraints
- 3.4.3.Opportunities
- 3.5.COVID-19 Impact Analysis on the market
- CHAPTER 4: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2. ELISA HEV IgM Test
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3. ELISA HEV IgG Test
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.4. RT-PCR Test
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
- CHAPTER 5: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2. Hospitals
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3. Diagnostic Centers
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- 5.4. Others
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country
- CHAPTER 6: HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Test Type
- 6.2.3 North America Market size and forecast, by End User
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Key market trends, growth factors and opportunities
- 6.2.4.1.2 Market size and forecast, by Test Type
- 6.2.4.1.3 Market size and forecast, by End User
- 6.2.4.2 Canada
- 6.2.4.2.1 Key market trends, growth factors and opportunities
- 6.2.4.2.2 Market size and forecast, by Test Type
- 6.2.4.2.3 Market size and forecast, by End User
- 6.2.4.3 Mexico
- 6.2.4.3.1 Key market trends, growth factors and opportunities
- 6.2.4.3.2 Market size and forecast, by Test Type
- 6.2.4.3.3 Market size and forecast, by End User
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Test Type
- 6.3.3 Europe Market size and forecast, by End User
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 Germany
- 6.3.4.1.1 Key market trends, growth factors and opportunities
- 6.3.4.1.2 Market size and forecast, by Test Type
- 6.3.4.1.3 Market size and forecast, by End User
- 6.3.4.2 France
- 6.3.4.2.1 Key market trends, growth factors and opportunities
- 6.3.4.2.2 Market size and forecast, by Test Type
- 6.3.4.2.3 Market size and forecast, by End User
- 6.3.4.3 UK
- 6.3.4.3.1 Key market trends, growth factors and opportunities
- 6.3.4.3.2 Market size and forecast, by Test Type
- 6.3.4.3.3 Market size and forecast, by End User
- 6.3.4.4 Italy
- 6.3.4.4.1 Key market trends, growth factors and opportunities
- 6.3.4.4.2 Market size and forecast, by Test Type
- 6.3.4.4.3 Market size and forecast, by End User
- 6.3.4.5 Spain
- 6.3.4.5.1 Key market trends, growth factors and opportunities
- 6.3.4.5.2 Market size and forecast, by Test Type
- 6.3.4.5.3 Market size and forecast, by End User
- 6.3.4.6 Rest of Europe
- 6.3.4.6.1 Key market trends, growth factors and opportunities
- 6.3.4.6.2 Market size and forecast, by Test Type
- 6.3.4.6.3 Market size and forecast, by End User
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Test Type
- 6.4.3 Asia-Pacific Market size and forecast, by End User
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 Japan
- 6.4.4.1.1 Key market trends, growth factors and opportunities
- 6.4.4.1.2 Market size and forecast, by Test Type
- 6.4.4.1.3 Market size and forecast, by End User
- 6.4.4.2 China
- 6.4.4.2.1 Key market trends, growth factors and opportunities
- 6.4.4.2.2 Market size and forecast, by Test Type
- 6.4.4.2.3 Market size and forecast, by End User
- 6.4.4.3 Australia
- 6.4.4.3.1 Key market trends, growth factors and opportunities
- 6.4.4.3.2 Market size and forecast, by Test Type
- 6.4.4.3.3 Market size and forecast, by End User
- 6.4.4.4 India
- 6.4.4.4.1 Key market trends, growth factors and opportunities
- 6.4.4.4.2 Market size and forecast, by Test Type
- 6.4.4.4.3 Market size and forecast, by End User
- 6.4.4.5 South Korea
- 6.4.4.5.1 Key market trends, growth factors and opportunities
- 6.4.4.5.2 Market size and forecast, by Test Type
- 6.4.4.5.3 Market size and forecast, by End User
- 6.4.4.6 Rest of Asia-Pacific
- 6.4.4.6.1 Key market trends, growth factors and opportunities
- 6.4.4.6.2 Market size and forecast, by Test Type
- 6.4.4.6.3 Market size and forecast, by End User
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Test Type
- 6.5.3 LAMEA Market size and forecast, by End User
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Key market trends, growth factors and opportunities
- 6.5.4.1.2 Market size and forecast, by Test Type
- 6.5.4.1.3 Market size and forecast, by End User
- 6.5.4.2 Saudi Arabia
- 6.5.4.2.1 Key market trends, growth factors and opportunities
- 6.5.4.2.2 Market size and forecast, by Test Type
- 6.5.4.2.3 Market size and forecast, by End User
- 6.5.4.3 South Africa
- 6.5.4.3.1 Key market trends, growth factors and opportunities
- 6.5.4.3.2 Market size and forecast, by Test Type
- 6.5.4.3.3 Market size and forecast, by End User
- 6.5.4.4 Rest of LAMEA
- 6.5.4.4.1 Key market trends, growth factors and opportunities
- 6.5.4.4.2 Market size and forecast, by Test Type
- 6.5.4.4.3 Market size and forecast, by End User
- CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top player positioning, 2021
- CHAPTER 8: COMPANY PROFILES
- 8.1 MP Biomedicals LLP
- 8.1.1 Company overview
- 8.1.2 Key Executives
- 8.1.3 Company snapshot
- 8.1.4 Operating business segments
- 8.1.5 Product portfolio
- 8.1.6 Business performance
- 8.1.7 Key strategic moves and developments
- 8.2 F. Hoffmann-La Roche Ltd.
- 8.2.1 Company overview
- 8.2.2 Key Executives
- 8.2.3 Company snapshot
- 8.2.4 Operating business segments
- 8.2.5 Product portfolio
- 8.2.6 Business performance
- 8.2.7 Key strategic moves and developments
- 8.3 Altona Diagnostics
- 8.3.1 Company overview
- 8.3.2 Key Executives
- 8.3.3 Company snapshot
- 8.3.4 Operating business segments
- 8.3.5 Product portfolio
- 8.3.6 Business performance
- 8.3.7 Key strategic moves and developments
- 8.4 PerkinElmer, Inc
- 8.4.1 Company overview
- 8.4.2 Key Executives
- 8.4.3 Company snapshot
- 8.4.4 Operating business segments
- 8.4.5 Product portfolio
- 8.4.6 Business performance
- 8.4.7 Key strategic moves and developments
- 8.5 Dia.Pro - Diagnostic Bioprobes s.r.l
- 8.5.1 Company overview
- 8.5.2 Key Executives
- 8.5.3 Company snapshot
- 8.5.4 Operating business segments
- 8.5.5 Product portfolio
- 8.5.6 Business performance
- 8.5.7 Key strategic moves and developments
- 8.6 Primerdesign Ltd
- 8.6.1 Company overview
- 8.6.2 Key Executives
- 8.6.3 Company snapshot
- 8.6.4 Operating business segments
- 8.6.5 Product portfolio
- 8.6.6 Business performance
- 8.6.7 Key strategic moves and developments
- 8.7 Mikrogen GmbH
- 8.7.1 Company overview
- 8.7.2 Key Executives
- 8.7.3 Company snapshot
- 8.7.4 Operating business segments
- 8.7.5 Product portfolio
- 8.7.6 Business performance
- 8.7.7 Key strategic moves and developments
- 8.8 Fortress Diagnostics
- 8.8.1 Company overview
- 8.8.2 Key Executives
- 8.8.3 Company snapshot
- 8.8.4 Operating business segments
- 8.8.5 Product portfolio
- 8.8.6 Business performance
- 8.8.7 Key strategic moves and developments
- 8.9 ELITechGroup
- 8.9.1 Company overview
- 8.9.2 Key Executives
- 8.9.3 Company snapshot
- 8.9.4 Operating business segments
- 8.9.5 Product portfolio
- 8.9.6 Business performance
- 8.9.7 Key strategic moves and developments
- 8.10 Beijing Wantai Biolog Pha Ent Co Ltd
- 8.10.1 Company overview
- 8.10.2 Key Executives
- 8.10.3 Company snapshot
- 8.10.4 Operating business segments
- 8.10.5 Product portfolio
- 8.10.6 Business performance
- 8.10.7 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 2. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGM TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 3. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR ELISA HEV IGG TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 4. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR RT-PCR TEST, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 5. GLOBAL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 6. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 7. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 8. HEPATITIS E DIAGNOSTIC TESTS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 9. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 10. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 11. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 12. NORTH AMERICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 13. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 14. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 15. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 16. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 17. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 18. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 19. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 20. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 21. EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 22. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 23. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 24. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 25. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 26. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 27. UK HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 28. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 29. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 30. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 31. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 32. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 33. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 34. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 35. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 36. ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 37. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 38. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 39. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 40. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 41. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 42. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 43. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 44. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 45. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 46. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 47. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 48. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 49. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 50. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 51. LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 52. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 53. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 54. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 55. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 56. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 57. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 58. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
- TABLE 59. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 60. MP BIOMEDICALS LLP: KEY EXECUTIVES
- TABLE 61. MP BIOMEDICALS LLP: COMPANY SNAPSHOT
- TABLE 62. MP BIOMEDICALS LLP: OPERATING SEGMENTS
- TABLE 63. MP BIOMEDICALS LLP: PRODUCT PORTFOLIO
- TABLE 64. MP BIOMEDICALS LLP: NET SALES
- TABLE 65. MP BIOMEDICALS LLP: KEY STRATERGIES
- TABLE 66. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 67. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 68. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
- TABLE 69. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 70. F. HOFFMANN-LA ROCHE LTD.: NET SALES
- TABLE 71. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
- TABLE 72. ALTONA DIAGNOSTICS: KEY EXECUTIVES
- TABLE 73. ALTONA DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 74. ALTONA DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 75. ALTONA DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 76. ALTONA DIAGNOSTICS: NET SALES
- TABLE 77. ALTONA DIAGNOSTICS: KEY STRATERGIES
- TABLE 78. PERKINELMER, INC: KEY EXECUTIVES
- TABLE 79. PERKINELMER, INC: COMPANY SNAPSHOT
- TABLE 80. PERKINELMER, INC: OPERATING SEGMENTS
- TABLE 81. PERKINELMER, INC: PRODUCT PORTFOLIO
- TABLE 82. PERKINELMER, INC: NET SALES
- TABLE 83. PERKINELMER, INC: KEY STRATERGIES
- TABLE 84. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: KEY EXECUTIVES
- TABLE 85. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: COMPANY SNAPSHOT
- TABLE 86. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: OPERATING SEGMENTS
- TABLE 87. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: PRODUCT PORTFOLIO
- TABLE 88. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: NET SALES
- TABLE 89. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L: KEY STRATERGIES
- TABLE 90. PRIMERDESIGN LTD: KEY EXECUTIVES
- TABLE 91. PRIMERDESIGN LTD: COMPANY SNAPSHOT
- TABLE 92. PRIMERDESIGN LTD: OPERATING SEGMENTS
- TABLE 93. PRIMERDESIGN LTD: PRODUCT PORTFOLIO
- TABLE 94. PRIMERDESIGN LTD: NET SALES
- TABLE 95. PRIMERDESIGN LTD: KEY STRATERGIES
- TABLE 96. MIKROGEN GMBH: KEY EXECUTIVES
- TABLE 97. MIKROGEN GMBH: COMPANY SNAPSHOT
- TABLE 98. MIKROGEN GMBH: OPERATING SEGMENTS
- TABLE 99. MIKROGEN GMBH: PRODUCT PORTFOLIO
- TABLE 100. MIKROGEN GMBH: NET SALES
- TABLE 101. MIKROGEN GMBH: KEY STRATERGIES
- TABLE 102. FORTRESS DIAGNOSTICS: KEY EXECUTIVES
- TABLE 103. FORTRESS DIAGNOSTICS: COMPANY SNAPSHOT
- TABLE 104. FORTRESS DIAGNOSTICS: OPERATING SEGMENTS
- TABLE 105. FORTRESS DIAGNOSTICS: PRODUCT PORTFOLIO
- TABLE 106. FORTRESS DIAGNOSTICS: NET SALES
- TABLE 107. FORTRESS DIAGNOSTICS: KEY STRATERGIES
- TABLE 108. ELITECHGROUP: KEY EXECUTIVES
- TABLE 109. ELITECHGROUP: COMPANY SNAPSHOT
- TABLE 110. ELITECHGROUP: OPERATING SEGMENTS
- TABLE 111. ELITECHGROUP: PRODUCT PORTFOLIO
- TABLE 112. ELITECHGROUP: NET SALES
- TABLE 113. ELITECHGROUP: KEY STRATERGIES
- TABLE 114. BEIJING WANTAI BIOLOG PHA ENT CO LTD: KEY EXECUTIVES
- TABLE 115. BEIJING WANTAI BIOLOG PHA ENT CO LTD: COMPANY SNAPSHOT
- TABLE 116. BEIJING WANTAI BIOLOG PHA ENT CO LTD: OPERATING SEGMENTS
- TABLE 117. BEIJING WANTAI BIOLOG PHA ENT CO LTD: PRODUCT PORTFOLIO
- TABLE 118. BEIJING WANTAI BIOLOG PHA ENT CO LTD: NET SALES
- TABLE 119. BEIJING WANTAI BIOLOG PHA ENT CO LTD: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1. SEGMENTATION OF HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031
- FIGURE 2. HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031
- FIGURE 3. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 4. PORTER FIVE-1
- FIGURE 5. PORTER FIVE-2
- FIGURE 6. PORTER FIVE-3
- FIGURE 7. PORTER FIVE-4
- FIGURE 8. PORTER FIVE-5
- FIGURE 9. HEPATITIS E DIAGNOSTIC TESTS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 10. HEPATITIS E DIAGNOSTIC TESTS MARKET,BY TEST TYPE,2021(%)
- FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGM TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ELISA HEV IGG TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF RT-PCR TEST HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 14. HEPATITIS E DIAGNOSTIC TESTS MARKET,BY END USER,2021(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF HOSPITALS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS HEPATITIS E DIAGNOSTIC TESTS MARKET, 2021 AND 2031(%)
- FIGURE 18. HEPATITIS E DIAGNOSTIC TESTS MARKET BY REGION,2021
- FIGURE 19. U.S. HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 20. CANADA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 21. MEXICO HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 22. GERMANY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 23. FRANCE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 24. UK HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 25. ITALY HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 26. SPAIN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 27. REST OF EUROPE HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 28. JAPAN HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 29. CHINA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 30. AUSTRALIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 31. INDIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 32. SOUTH KOREA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 33. REST OF ASIA-PACIFIC HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 34. BRAZIL HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 35. SAUDI ARABIA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 36. SOUTH AFRICA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 37. REST OF LAMEA HEPATITIS E DIAGNOSTIC TESTS MARKET,2021-2031($MILLION)
- FIGURE 38. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 41. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 42. COMPETITIVE DASHBOARD
- FIGURE 43. COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 44. TOP PLAYER POSITIONING, 2021
- FIGURE 45. MP BIOMEDICALS LLP.: NET SALES ($MILLION)
- FIGURE 46. F. HOFFMANN-LA ROCHE LTD..: NET SALES ($MILLION)
- FIGURE 47. ALTONA DIAGNOSTICS.: NET SALES ($MILLION)
- FIGURE 48. PERKINELMER, INC.: NET SALES ($MILLION)
- FIGURE 49. DIA.PRO - DIAGNOSTIC BIOPROBES S.R.L.: NET SALES ($MILLION)
- FIGURE 50. PRIMERDESIGN LTD.: NET SALES ($MILLION)
- FIGURE 51. MIKROGEN GMBH.: NET SALES ($MILLION)
- FIGURE 52. FORTRESS DIAGNOSTICS.: NET SALES ($MILLION)
- FIGURE 53. ELITECHGROUP.: NET SALES ($MILLION)
- FIGURE 54. BEIJING WANTAI BIOLOG PHA ENT CO LTD.: NET SALES ($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook